MEIP MEI Pharma, Inc. Stock Quote

MEIP [NASD]

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	0.49%	Shs Outstand	133.06M	Perf Week	-6.90%
Market Cap	65.45M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	0.00%	Shs Float	132.50M	Perf Month	-8.12%
Income	-34.80M	PEG	-	EPS next Q	-0.19	Inst Own	38.10%	Short Float	3.84%	Perf Quarter	-23.57%
Sales	48.70M	P/S	1.34	EPS this Y	29.10%	Inst Trans	-14.93%	Short Ratio	2.08	Perf Half Y	-75.72%
Book/sh	0.51	P/B	0.95	EPS next Y	-49.00%	ROA	-18.50%	Target Price	5.17	Perf Year	-83.23%
Cash/sh	1.25	P/C	0.39	EPS next 5Y	-0.10%	ROE	-62.00%	52W Range	0.41 - 3.55	Perf YTD	-81.91%
Dividend	-	P/FCF	-	EPS past 5Y	9.50%	ROI	-122.10%	52W High	-85.60%	Beta	0.81
Dividend %	-	Quick Ratio	7.70	Sales past 5Y	-	Gross Margin	-	52W Low	26.20%	ATR	0.04
Employees	76	Current Ratio	7.70	Sales Q/Q	304.20%	Oper. Margin	-	RSI (14)	47.10	Volatility	6.66% 7.19%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	76.40%	Profit Margin	-71.60%	Rel Volume	1.54	Prev Close	0.48
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Sep 08 AMC	Payout	-	Avg Volume	2.45M	Price	0.51
Recom	2.30	SMA20	-3.47%	SMA50	-5.59%	SMA200	-60.16%	Volume	811,324	Change	5.80%

Mar-25-22

Downgrade

Wells Fargo

Overweight → Equal Weight

$13 → $2

Mar-25-22

Downgrade

Stifel

Buy → Hold

$6 → $2

Mar-25-22

Downgrade

Jefferies

Buy → Hold

$4 → $1

Feb-03-22

Initiated

Jefferies

Buy

Sep-22-20

Initiated

Alliance Global Partners

Buy

May-29-20

Initiated

SunTrust

Buy

$16

Dec-20-18

Initiated

H.C. Wainwright

Buy

$10

Dec-20-18

Initiated

H.C. Wainwright

Buy

Jul-27-18

Upgrade

Stifel

Hold → Buy

$2.50 → $7

Jul-13-18

Initiated

SunTrust

Buy

$12

Apr-18-16

Reiterated

Wedbush

Neutral

$3 → $2

Mar-23-15

Downgrade

ROTH Capital

Buy → Neutral

$14 → $2.50

Dec-18-14

Reiterated

ROTH Capital

Buy

$22 → $14

Oct-16-14

Reiterated

ROTH Capital

Buy

$20 → $22

Jul-08-14

Resumed

Brean Capital

Buy

$16

Oct-22-13

Reiterated

Stifel

Buy

$11 → $15

Apr-15-13

Initiated

Stifel

Buy

$11

Sep-06-22 08:00AM	MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022 Business Wire
Sep-01-22 04:00PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
08:00AM	MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022 Business Wire
Aug-18-22 10:35AM	MEI Pharma (NASDAQ:MEIP) investors are sitting on a loss of 79% if they invested a year ago Simply Wall St.
Aug-01-22 04:00PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-18-22 08:00AM	MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy Business Wire
Jul-01-22 04:00PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-22-22 08:00AM	MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer Business Wire
Jun-10-22 03:00AM	MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress Business Wire -9.68%
Jun-04-22 04:00PM	MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 Business Wire
Jun-01-22 04:00PM	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-26-22 05:00PM	MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022 Business Wire
May-23-22 05:35PM	MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates Zacks -6.71%
04:20PM	MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights Business Wire
May-17-22 08:00AM	MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022 Business Wire
May-12-22 02:21PM	We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate Simply Wall St.
10:00AM	MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress Business Wire
May-04-22 09:15AM	Pacira (PCRX) Q1 Earnings Miss Estimates Zacks +9.46%
May-02-22 04:00PM	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire +11.64%
Apr-08-22 01:00PM	MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022 Business Wire
Apr-01-22 04:01PM	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-28-22 05:41PM	Revenue Downgrade: Here's What Analysts Forecast For MEI Pharma, Inc. (NASDAQ:MEIP) Simply Wall St. -14.86%
Mar-25-22 02:47PM	Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update Benzinga -65.15%
02:29PM	Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug Zacks
Mar-24-22 04:01PM	MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA Business Wire
Mar-08-22 04:30PM	MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 Business Wire
Mar-01-22 04:01PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-12-22 07:07AM	Analyst Forecasts Just Became More Bearish On MEI Pharma, Inc. (NASDAQ:MEIP) Simply Wall St.
Feb-10-22 07:25PM	MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights Business Wire
Feb-07-22 08:00AM	MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments Business Wire
Feb-01-22 04:01PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-27-22 03:01PM	Will MEI Pharma, Inc. (MEIP) Report Negative Q2 Earnings? What You Should Know Zacks
Jan-15-22 08:50AM	Those who invested in MEI Pharma (NASDAQ:MEIP) five years ago are up 62% Simply Wall St.
Jan-03-22 04:01PM	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-06-21 04:00PM	MEI Pharma Announces Closing of Public Offering of Common Stock Business Wire
Dec-03-21 04:00PM	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire -7.04%
Dec-01-21 08:46PM	MEI Pharma Announces Pricing of Public Offering of Common Stock Business Wire -10.24%
12:56PM	MEI Pharma: Theres More Upside Ahead, Says Analyst Who Made a Winning Call TipRanks
10:19AM	MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Cut Their EPS Forecasts Substantially Simply Wall St.
08:44AM	Do Options Traders Know Something About MEI Pharma (MEIP) Stock We Don't? Zacks
Nov-30-21 04:00PM	MEI Pharma Announces Proposed Public Offering of Common Stock Business Wire +37.55%
07:00AM	MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma Business Wire
Nov-29-21 04:00PM	MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma Business Wire -6.13%
Nov-23-21 08:00AM	MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors Business Wire
Nov-10-21 06:35PM	MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights Business Wire
08:00AM	MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma Business Wire
Nov-04-21 09:00AM	MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting Business Wire
Nov-02-21 03:02PM	MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Nov-01-21 04:01PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-22-21 10:46AM	MEI Pharma, Inc. (NASDAQ:MEIP) Is Expected To Breakeven In The Near Future Simply Wall St.
Oct-06-21 11:21AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 TipRanks +10.98%
Oct-01-21 04:00PM	MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-22-21 08:00AM	MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference PR Newswire
Sep-07-21 09:03AM	Companies Like MEI Pharma (NASDAQ:MEIP) Are In A Position To Invest In Growth Simply Wall St.
Sep-03-21 04:05PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Sep-02-21 05:45PM	MEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4 Zacks
04:05PM	MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights PR Newswire
08:00AM	MEI Pharma to Present at Two Healthcare Conferences PR Newswire
Aug-26-21 08:00AM	MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021 PR Newswire
Aug-18-21 10:36AM	Mei (MEIP) Begins Phase III Study for B-Cell Malignancies Zacks
Aug-17-21 08:00AM	MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma PR Newswire
Aug-05-21 04:01PM	MEI Pharma Announces Planned Chief Financial Officer Transition PR Newswire
Aug-02-21 04:01PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-29-21 05:54PM	MEI Pharma Inc (MEIP): Are Hedge Funds Right About This Stock? Insider Monkey
Jul-16-21 05:10AM	What You Need To Know About MEI Pharma, Inc.'s (NASDAQ:MEIP) Investor Composition Simply Wall St.
Jul-07-21 08:00AM	MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer PR Newswire
Jul-01-21 04:01PM	MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-09-21 06:00AM	MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program PR Newswire
Jun-07-21 08:00AM	MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib PR Newswire
Jun-04-21 08:00AM	MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting PR Newswire
May-19-21 05:00PM	MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021 PR Newswire
May-12-21 10:00AM	MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress PR Newswire -9.77%
04:42AM	The MEI Pharma (NASDAQ:MEIP) Share Price Is Up 150% And Shareholders Are Boasting About It Simply Wall St.
May-06-21 06:55PM	MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights PR Newswire
Apr-30-21 09:00AM	MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer PR Newswire
Apr-29-21 05:06PM	Analysts Estimate MEI Pharma, Inc. (MEIP) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-13-21 07:00AM	MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA) PR Newswire
Apr-12-21 12:53PM	MEI Pharma Presents Positive Preclinical Data For Cancer Drug Voruciclib SmarterAnalyst
Apr-10-21 08:30AM	MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers PR Newswire
Apr-05-21 08:00AM	MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire +7.37%
Mar-12-21 10:50PM	MEI PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of MEI Pharma, Inc. - MEIP Business Wire
Mar-10-21 04:30PM	MEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical Models PR Newswire
Mar-02-21 08:00AM	MEI Pharma to present at the virtual H.C. Wainwright Global Life Sciences Conference 2021 PR Newswire
Feb-11-21 12:02AM	Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP) Revenues Simply Wall St.
Feb-05-21 10:50PM	MEI PHARMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP PR Newswire +17.70%
Feb-04-21 05:35PM	MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights PR Newswire
Jan-28-21 12:32PM	MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks +6.04%
Jan-14-21 02:45AM	What Type Of Shareholders Own The Most Number of MEI Pharma, Inc. (NASDAQ:MEIP) Shares? Simply Wall St.
Jan-04-21 07:00AM	MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update PR Newswire
Dec-18-20 10:50PM	MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP Business Wire
Dec-15-20 08:40PM	Is MEIP A Good Stock To Buy Now? Insider Monkey
Nov-15-20 09:20AM	Growth Investors: Industry Analysts Just Upgraded Their MEI Pharma, Inc. (NASDAQ:MEIP) Revenue Forecasts By 25% Simply Wall St.
Nov-10-20 04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights PR Newswire +5.19%
Nov-09-20 08:00AM	MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences PR Newswire
Oct-30-20 11:03AM	A Look At MEI Pharma's (NASDAQ:MEIP) CEO Remuneration Simply Wall St.
Oct-23-20 06:22PM	Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders Business Wire

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience